Table 2.
Immune-related adverse events (n = 20)
| Number of patients with event (%) | |||
|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | |
| Any immune-related adverse event | 9 (45%) | 7 (35%) | 2 (10%) |
| Infusion-related reaction | 2 (10%) | 3 (15%) | – |
| Fatigue | 4 (20%) | – | – |
| Fever | – | 4 (20%) | – |
| Arthralgia | 1 (5%) | 1 (5%) | – |
| Hypothyroidism | 1 (5%) | 1 (5%) | – |
| Diarrhea | – | – | 1 (5%) |
| Headache | – | – | 1 (5%) |
| Hepatitis | – | – | 1 (5%) |
| Photosensitivity | 1 (5%) | – | – |
| Rash maculopapular | 1 (5%) | – | – |
All AEs that were deemed at least possibly related to atezolizumab are shown in this table. This is regardless of the possible relationship with chemotherapy.